Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating reissued by research analysts at Numis Securities Ltd in a report issued on Wednesday. They presently have a GBX 933 ($12.18) price target on the stock. Numis Securities Ltd’s price objective would indicate a potential upside of 36.60% from the stock’s previous close.
Other research analysts also recently issued research reports about the company. Peel Hunt reaffirmed a “buy” rating and issued a GBX 1,000 ($13.05) price target on shares of Clinigen Group PLC in a research note on Thursday, June 9th. N+1 Singer reaffirmed a “buy” rating and issued a GBX 800 ($10.44) price target on shares of Clinigen Group PLC in a research note on Wednesday. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a GBX 800 ($10.44) price target on shares of Clinigen Group PLC in a research note on Wednesday, July 20th. Five research analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of GBX 856.60 ($11.18).
Shares of Clinigen Group PLC (LON:CLIN) opened at 691.50 on Wednesday. Clinigen Group PLC has a 12 month low of GBX 492.75 and a 12 month high of GBX 739.50. The firm’s market capitalization is GBX 771.71 million. The company has a 50 day moving average of GBX 653.77 and a 200-day moving average of GBX 598.48.
The firm also recently announced a dividend, which will be paid on Friday, November 25th. Shareholders of record on Thursday, November 3rd will be given a GBX 2.70 ($0.04) dividend. This represents a yield of 0.38%. The ex-dividend date is Thursday, November 3rd. This is a boost from Clinigen Group PLC’s previous dividend of $1.30.
Clinigen Group PLC Company Profile
Clinigen Group plc is a United Kingdom-based global pharmaceutical and services company. The Company consists of four businesses that provide medicines to patients with unmet needs, through clinical trials, licensed and unlicensed supply. It operates through four segments: Clinigen Clinical Trial Services (CTS), Idis Managed Access (MA), Idis Global Access (GA) and Clinigen Specialty Pharmaceuticals (SP).
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.